ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Feb 2026
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
March 2026
Nuclear Technology
February 2026
Fusion Science and Technology
January 2026
Latest News
Fusion energy: Progress, partnerships, and the path to deployment
Over the past decade, fusion energy has moved decisively from scientific aspiration toward a credible pathway to a new energy technology. Thanks to long-term federal support, we have significantly advanced our fundamental understanding of plasma physics—the behavior of the superheated gases at the heart of fusion devices. This knowledge will enable the creation and control of fusion fuel under conditions required for future power plants. Our progress is exemplified by breakthroughs at the National Ignition Facility and the Joint European Torus.
Douglass L. Henderson, Mohamed E. Sawan, Gregory A. Moses
Fusion Science and Technology | Volume 13 | Number 4 | May 1988 | Pages 594-615
Technical Paper | ICF Target | doi.org/10.13182/FST88-A25137
Articles are hosted by Taylor and Francis Online.
Biological dose rate calculations have been performed for a point external to the diode vacuum casing of the proposed Light Ion Fusion Target Development Facility for times following an operational period of 1 month. The primary diode material considered is Type 304LN stainless steel, with an alternative material of Al-6061-T6. Using a realistic pulse-sequence calculation scheme to account for the pulsed operation mode of the facility, it is shown that for both the stainless steel and aluminum diodes the dose rates external to the diode vacuum casing are > 1 rem/h after a 1-day shutdown period. After a 1-week shutdown period, the dose rates have dropped to 90 and 12 mrem/h, respectively.